Merck KGaA announced that its division Merck Serono has been granted marketing authorization by the European Commission for its product Cyanokit (active substance: hydroxocobalamin) for the treatment of known or suspected cyanide poisoning in both adults and the pediatric population. Cyanokit is the first cyanide antidote that is approved via the European Centralized Procedure. Cyanokit is the only cyanide antidote approved in the European Union, the United States of America and Japan.